Advisory Research Inc. held its stake in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,847 shares of the medical research company’s stock at the end of the 2nd quarter. Advisory Research Inc.’s holdings in Edwards Lifesciences Corporation were worth $1,491,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of EW. Financial Counselors Inc. grew its position in Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock worth $1,283,000 after acquiring an additional 282 shares in the last quarter. Westpac Banking Corp grew its position in Edwards Lifesciences Corporation by 13.5% in the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock worth $1,681,000 after acquiring an additional 1,691 shares in the last quarter. Principal Financial Group Inc. grew its position in Edwards Lifesciences Corporation by 41.9% in the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock worth $55,086,000 after acquiring an additional 137,643 shares in the last quarter. Nicholas Investment Partners LP purchased a new position in Edwards Lifesciences Corporation in the second quarter worth $5,904,000. Finally, Swiss National Bank grew its position in Edwards Lifesciences Corporation by 2.4% in the second quarter. Swiss National Bank now owns 775,898 shares of the medical research company’s stock worth $91,742,000 after acquiring an additional 18,400 shares in the last quarter. 82.12% of the stock is currently owned by institutional investors and hedge funds.
Shares of Edwards Lifesciences Corporation (EW) traded down 0.31% during mid-day trading on Thursday, hitting $110.13. 77,146 shares of the stock traded hands. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45. The firm has a 50 day moving average of $111.58 and a 200 day moving average of $111.24. The stock has a market cap of $23.40 billion, a price-to-earnings ratio of 42.20 and a beta of 0.62.
Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm had revenue of $842.00 million for the quarter, compared to the consensus estimate of $839.16 million. During the same period in the prior year, the firm posted $0.76 earnings per share. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.
In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $108.86, for a total transaction of $576,958.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The disclosure for this sale can be found here. Insiders have sold 182,201 shares of company stock worth $20,768,154 over the last three months. 2.13% of the stock is currently owned by insiders.
Several analysts have issued reports on the stock. SunTrust Banks, Inc. upped their price target on shares of Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Jefferies Group LLC restated a “buy” rating and set a $115.00 price target on shares of Edwards Lifesciences Corporation in a research report on Friday, June 30th. Canaccord Genuity restated a “buy” rating and set a $150.00 price target on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Stifel Nicolaus reaffirmed a “buy” rating and set a $130.00 price objective (up from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Finally, Bank of America Corporation upped their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Seven analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and an average price target of $120.75.
Edwards Lifesciences Corporation Profile
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.